We are writing with the exciting news that Mitsubishi Tanabe is announcing a Phase 3 trial for MT-7117 for patients with EPP.
The hard work of those who participated in the Phase 2 trial paved the way for this FIRST clinical trial that includes adolescents.
Trial Description: A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, And Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Treatment: Oral medication (pills), once daily in the morning with or without food Duration: 26 weeks plus optional 26 week double-blinded extension.
Endpoint: Increased pain free light exposure in adults and adolescents with a history of phototoxic reactions from EPP or XLP.
Study Sites: There will be 12 study sites in the US, followed by global study sites across multiple countries.
Age Range: Patients age 12- 75 Travel will be included and will be arranged by a concierge service trained on EPP/XLP.
Please contact the American Porphyria Foundation for more information and we will connect you with a study site nearest you.
OR call 866-APF-3635 301-347-7166